XenoPort unveils disappointing data for acid reflux drug

12/2/2008 | Reuters · Bloomberg

XenoPort reported midstage trial results showing that XP19986, a treatment for gastroesophageal reflux disease, did not demonstrate a significant difference versus placebo in decreasing heartburn. The company said it intends to conduct further studies after finding that the drug worked in patients who benefited at least partially from proton pump inhibitors.

View Full Article in:

Reuters · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR